Drug Trial Radar · NCT07893600
Efficacy and Safety of OsrhCT Before Upper Endoscopy on Improving Visualization of the Gastric Mucosa.
Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Oct 27, 2026
Primary completion
Dec 22, 2026
Study completion Dec 22, 2026
Sponsor
- Lead sponsor
- Healthgen Biotechnology Corp.Industry
- Sponsor type
- Industry
- First posted
- Oct 26, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study was designed to evaluate efficacy and safety of OsrhCT before upper endoscopy on visibility of gastric mucosa. A total of 40 subjects (both male and female) are expected to be enrolled in this trial.
Conditions
- Gastric Mucosal Lesion
Interventions
Recombinant Human Chymotrypsin(OsrhCT) 4000UDrug
Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, 4,000U/bag, freeze-dried powder
Placebo for Recombinant Human Chymotrypsin(OsrhCT)Drug
Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, 0 U/bag, freeze-dried powder
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total visibility score (TVS) evaluated by blinded endoscopistsTime frame: Through study completion, up to 2 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.